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Exposure of a nontransformed, continuous line of 
epithelial cells derived from rat liver (WB cells) to 
epidermal  growth  factor,  angiotensin 11, [Ardlvaso- 
pressin,  and  epinephrine  resulted  in  rapid accumula- 
tion of the inositol phosphates (InsP) InsP1, InsPz,  and 
InsP,. Although short-term (5-60 min) pretreatment 
of WB cells with the phorbol ester 4b-phorbol 128- 
myristate  13a-acetate (PMA) markedly  attenuated 
InsP accumulation in response to all agonists, the  in- 
hibitory effects on the  InsP response were lost after 2 
h incubation with PMA; and,  with extended (6-24 h) 
preincubation, a time-dependent potentiation of the 
InsP response to  angiotensin 11, epidermal  growth fac- 
tor  and  [Ard]vasopressin  was observed. The InsP  re- 
sponse during  a  15-min challenge with angiotensin I1 
in cells pretreated  for 18 h  with 600 nM and 10 pM 
PMA was  increased by  2-%fold and 4-6-fold, respec- 
tively. Long-term (18 h) treatment  with 600 nM and 
10 PM PMA caused a similar 90-100% loss of measur- 
able Ca2+/phospholipid-dependent enzyme (protein  ki- 
nase C) activity in cytosolic and soluble particulate 
fractions.  The effects of long-term PMA pretreatment 
do not represent a general enhancement of hormone 
responsiveness since  the InsP response to epinephrine 
was not affected. In control cells, the  InsP response to 
angiotensin I1 and  epinephrine desensitized very rap- 
idly. Long-term pretreatment  with PMA greatly  re- 
duced the  contribution of agonist-induced desensitiza- 
tion to the angiotensin I1 response; in contrast, the 
extent of desensitization occurring  during incubation 
of WB cells with  epinephrine  was  unaltered by long- 
term treatment with PMA suggesting that an addi- 
tional mechanism may be involved in al-adrenergic 
receptor desensitization. No PMA-induced change in 
resting levels of [3H]phosphoinositides or  the metabo- 
lism of exogenous [3H]inositol 1,4,5-trisphosphate by 
WB homogenates occurred. Stimulation of InsP  for- 
mation in intact cells by NaF and  activation of phos- 
pholipase C by GTPrS in membranes both were unal- 
tered by short-term or long-term PMA pretreatment. 
These data  are consistent with  the  idea that following 
long-term treatment of  WB cells with PMA, the occur- 
rence of agonist-induced desensitization of receptors 
linked  to the phosphoinositide/Ca’+ signaling system is 
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reduced, apparently at least in part due to the loss of 
contribution of a negative feedback regulatory role of 
protein  kinase C. 
Stimulation of a variety of cell surface receptors results in 
activation of phospholipase C  and rapid hydrolysis of mem- 
brane PtdIns(4,5)Pz’ to generate two second messengers, 
Ins(1,4,5)P3 and diacylglycerol (DAG). Ins(1,4,5)P3 releases 
Ca2+ from intracellular stores whereas DAG, in concert with 
membrane phospholipids and Ca2+, promotes translocation to 
the plasma membrane and activation of CaZc/phospholipid- 
dependent enzyme (protein kinase C) (1-3). The tumor-pro- 
moting phorbol esters mimic the effects of endogenously 
produced DAG in activating protein kinase C (3) and,  thus, 
have provided a powerful tool to study the role of protein 
kinase C in cell function. Short-term activation of protein 
kinase C with phorbol esters results in the inhibition of 
agonist-induced PtdIns(4,5)P2 hydrolysis (2, 4-9) and Ca2+ 
mobilization (2, 7-10) in a variety of tissues. These observa- 
tions suggest that protein kinase C activity may play an 
important role in the feedback regulation of the receptor- 
operated Ins( 1,4,5)P,/Ca2+ signaling pathway. 
The contribution of protein kinase C to cellular function 
also has been examined by the blockade of its activity. Several 
pharmacological agents (11) have been reported to inhibit 
protein kinase C activity with partial selectivity; and  sphin- 
gosine, a major lipid component of the plasma membrane, has 
been shown to  inhibit competitively the binding of phorbol 
esters  to  protein kinase C (12) and  to  inhibit protein kinase 
C-mediated processes (13,14). Alternatively, chronic exposure 
of cells to phorbol esters results in down-regulation of protein 
kinase C  and  a concomitant loss of phorbol ester responsive- 
ness (3, 15-18). 
WB cells are  a nontransformed, continuous line of epithelial 
cells derived from rat liver that have  been  shown  previously 
The abbreviations used are: PtdIns(4,5)P2, phosphatidylinositol 
4,5-bisphosphate; PMA, 4p-phorboll2p-myristate l3a-acetate; DAG, 
diacylglycerol; EGF, epidermal growth factor; InsP, total inositol 
phosphates including inositol monophosphate (InsP,), inositol bis- 
phosphate (Imp2), inositol trisphosphate  (InsP,), and inositol tetra- 
kisphosphate; Ins(l,4)P2, inositol 1,4-bisphosphate; Ins(1,3,4)P3, ino- 
sitol 1,3,4-trisphosphate; Ins(1,4,5)P$, inositol 1,4,5-trisphosphate; 
PtdIns, phosphatidylinositol; PtdIns-4-P, phosphatidylinositol 4- 
phosphate; G-protein, guanine nucleotide regulatory protein; GTPyS, 
guanosine 5’-0-(3-thio)trisphosphate; HEPES, 4-(2-hydroxylethyl)- 
1-piperazineethanesulfonic acid; EGTA, [ethylenebis(oxyethylene- 
nitri1o)ltetraacetic acid; BSA, bovine serum albumin; HPLC, high 
performance liquid chromatography; Me2S0, dimethyl sulfoxide. 
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to express functional  EGF receptors (19). We have found that 
activation of EGF, angiotensin 11, [Argjvasopressin,  and a1- 
adrenergic receptors on WB cells results in the hydrolysis 
of phosphoinositides.' To investigate the role of protein 
kinase C activity in the regulation of agonist-stimulated 
PtdIns(4,5)P2 hydrolysis and  InsP formation in WB cells, we 
have characterized hormone- and growth factor-stimulated 
InsP formation under conditions where protein kinase C has 
been down-regulated by chronic exposure to  the phorbol ester, 
PMA. We report that, although acute activation of protein 
kinase C by PMA results in a marked reduction in the 
accumulation of InsP  to all agonists tested, down-regulation 
of protein kinase C reverses this effect of phorbol ester  and 
results in a selective and marked increase in  the levels of InsP 
formed to angiotensin 11, [Arg8]vasopressin, and EGF but, 
surprisingly, not to epinephrine. Studies designed to elucidate 
possible mechanisms underlying this sensitization of the 
phosphoinositide signaling pathway are described. 
EXPERIMENTAL  PROCEDURES 
Materials-EGF was prepared from mouse maxillary glands as 
previously described (21). Angiotensin I1 and [Ar$]vasopressin were 
obtained from Boehringer Mannheim;  epinephrine, MezSO, BSA, and 
PMA were obtained from Sigma. my~-[~H]Inositol (15 Ci/mol) was 
obtained from American Radiolabeled Chemical Co. (St. Louis, MO). 
WB cells were generously provided by Dr. J. W. Grisham, The 
University of North Carolina at  Chapel Hill. 
Cell Culture-WB cells were grown as previously described (19). 
WB cell stock cultures were maintained at  37 "C in an 8% COZ, 
humidified atmosphere  in Richter's Improved MEM containing in- 
sulin (4 mg/liter) and L-glutamine (Irvine Scientific, Santa Ana, CA) 
supplemented with 10% fetal calf serum and antibiotics. All stock 
plates were confluent and 5-7 days old at  the time of subculture. 
Subculture was accomplished by aspirating the medium and detaching 
the cells by addition of 1 ml of trypsin (0.25%) in isotonic buffer for 
30 min. Cells were seeded at  a 1:5 dilution onto 100-mm plastic 
culture  plates  (Falcon), and  the medium was replaced every 4th day. 
For most experiments, cells were routinely grown to confluency on 
12-well plastic culture  plates  (Costar). 
Analysis of Inositol Phosphates in Intact Cells-For all experiments, 
WB cells were  grown until contact-inhibited and in  a confluent state; 
cells were used 1 day postconfluency. WB cells were labeled for 18- 
24 h with 5-20 pCi/ml [3H]inositol  in inositol-free Dulbecco's modi- 
fied Eagle's medium containing high glucose (4500 mg/liter) and 
supplemented with 5% fetal calf serum. When appropriate, PMA (10 
mM stock) or vehicle (MezSO) was added directly to the labeling 
medium to a specified final  concentration and for a specified time of 
pretreatment. At the end of the labeling period, the medium was 
replaced by Eagle's minimal essential medium-HEPES (25 mM) 
containing 10 mM LiC1, unless otherwise specified, and incubated for 
in  the same medium (0.1% BSA final was added for EGF) and added 
10 min at 37 "C in  the presence of room air. Agonists were prepared 
for the indicated times, and  the reactions were terminated by the 
addition of cold 5% perchloric acid. Samples were processed and 
analyzed for the presence of water-soluble [3H]inositol phosphates by 
anion exchange chromatography as described previously (22) with 
modifications (23). 
Determination of Imp3 Isomers by HPLC-InsP, isomers were 
analyzed by HPLC using the method of Irvine et al. (24) and as 
described previously with minor modifications (25). ,H-Labeled in- 
ternal  standards of Ins(1,3,4)P3,  Ins(1,4,5)P3, and Ins(1,3,4,5)P4 were 
prepared and kindly supplied by Drs. Len Stephens, Phil Hawkins, 
and C. P. Downes, Smith Kline & French Research Ltd., Welwyn, 
England. 
Measurement of Phosphoinositides-3H-Labeled PtdIns,  PtdIns-4- 
P,  and  PtdIns(4,5)P2 were quantitated as described previously (26) 
employing modifications of the procedure described by Creba et al. 
(27). 
Measurement of Inositol Phosphates in Membrane Preparatiom- 
Confluent cultures of WB cells in 100-mm dishes were labeled over- 
'Earp, H. s., Hepler, J. R., Petch, L. A., Miller, A., Raymond, V. 
W., McCune, B.  K.,  Lee, L. W., Grisham, J. W., and Harden, T. K., 
submitted for publication. 
night with 10 pCi/ml [3H]inositol as described above. To prepare WB 
membranes, the labeling medium  was  removed and replaced with cold 
hypoosmotic lysis buffer (1 mM HEPES, 1 mM EGTA, pH 7.0) and 
incubated at 4 "C for 20-30 min. The lysis buffer was removed by 
aspiration, the cells were scraped from the dishes with a rubber 
policeman, and  the tissue was collected for centrifugation. The lysates 
were resuspended in approximately 8 ml of cold lysis buffer and 
pelleted twice by centrifugation at 15,000 X g for 10 min. The 
membrane pellet was resuspended in HEPES (10 mM, pH 7.01, 
pelleted by centrifugation, and resuspended in the same buffer for 
assay. Assay of phospholipase C activity and  the formation of InsP 
in washed WB membranes to agonist and guanine nucleotides was as 
described previously by Harden  et al. (26). 
Measurement of Protein Kinase C Actiuity-Confluent cultures of 
WB cells were treated for 18 h with 0, 600 nM, or 10 pM PMA, 
homogenized, and  then separated into cytosolic and particulate frac- 
tions by 105,000 X g centrifugation, The particulate fraction was 
extracted with 0.35% Triton,  and  then both the cytosolic and soluble 
particulate fractions were assayed for protein kinase C activity as 
described previously (28) by measuring the phosphatidylserine (63 
and 600 p ~ ) -  and diacylglycerol (39 and 80 pM)-mediated transfer of 
32P from [y3'P]ATP  to substrate, i.e. HPLC-purified N-bromosuc- 
cinimide cleavage fragment of lysine-rich histone (29). 
Measurement of Ins(1,4,5)P3 Metabolism in WB Homogenutes- 
Confluent cultures of WB cells in 100-mm dishes were treated for 18 
h with PMA or vehicle and lysed with hypoosmotic buffer as described 
above. Lysis buffer was  removed by aspiration, the lysed cells were 
removed from the culture dishes with a rubber policeman, and  the 
lysates were collected in a glass tube. Lysates were maintained at 
4 "C and subjected to three consecutive 5-9 bursts of sonication with 
a sonicator probe (Ystrom). Twenty p1 of lysate was added to 80 pl 
of an intracellular buffer (26) containing [3H]Ins(1,4,5)P3 (1 Ci/mmol, 
Amersham) in a glass tube at 4 "C, vortexed, and incubated for the 
indicated times at 37 "C in the absence of  LiC1. The assay was 
terminated by the addition of cold 5% perchloric acid and 3H-labeled 
inositol phosphates were processed and resolved by  Dowex chroma- 
tography as described above. 
Statistical Analysis-Statistical analysis of the  data was performed 
using a two-tailed Student's  t  test. 
RESULTS 
Stimulation of WB cells with maximally effective concen- 
trations of EGF (300 ng/ml), epinephrine (10 p ~ ) ,  angiotensin 
I1 (1 p ~ ) ,  and [Arg8]vasopressin (1 p ~ )  resulted in a signifi- 
cantly  enhanced accumulation of InsP,, InsP,, and Inspa  as 
compared to unstimulated cells (Fig. 1). It has been reported 
previously that  short-term pretreatment of cells with 0.1-1.0 
p~ PMA maximally activates protein kinase C and that long- 
term  pretreatment with similar concentrations of PMA re- 
sults in down-regulation of protein kinase C as assessed by 
measurable enzyme activity, immunoreactivity, and respon- 
siveness to phorbol ester (3, 15-18). As illustrated in Table I, 
pretreatment of WB cells with 600 nM PMA for 15 min 
resulted in an 85-100%  loss of response to agonists. In con- 
trast, overnight (18 h) pretreatment of WB cells with 600 nM 
PMA resulted in markedly different changes in hormone 
responsiveness. The  InsP response to epinephrine was similar 
to  that observed with control cells, but InsP accumulation in 
response to angiotensin I1 and  EGF were enhanced signifi- 
cantly over control responses (Table  I). As illustrated in Fig. 
2, PMA-induced potentiation of agonist-stimulated formation 
of InsP occurred without a noticeable change in the for 
either agonist (i.e 30 ng/ml and 1 nM for EGF  and angiotensin 
11, respectively). Incubation of WB cells with 10 p~ of the 
inactive analogue of PMA, 4a-phorbol, for 15 min or 18 h had 
no effect on hormone responsiveness (data  not shown). 
A 15-min pretreatment of WB cells with various concentra- 
tions of PMA resulted in a concentration-dependent loss of 
response to angiotensin 11; maximal inhibition (85%) of hor- 
mone responsiveness was observed with 1-10 p~ PMA (Fig. 
3). Similarly, 15-min pretreatment with 10 pM PMA com- 
pletely blocked EGF-, epinephrine-, and [Ar$]vasopressin- 
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FIG. 1. Hormone- and growth factor-stimulated accumula- 
tion  of inositol phosphates in WB cells. WB  cells  were  labeled 
overnight  with 20 pCi/ml [3H]inositol and then treated with  vehicle 
(0.1% BSA), 300 p M  epidermal  growth  factor (EGF, stippled), 10 p~ 
epinephrine (EPZ, white), 1 p~ angiotensin I1 (AZI, hatched), or 1 
p M  [Ar$]vasopressin (AVP, black) for 5 min in the presence of 10 
mM LiCl. Samples were  assayed  for  [3H]inositol  phosphates by anion 
exchange  chromatography. The  data are expressed as  the increase  in 
3H radioactivity over  vehicle. The levels of 3H  label  measured  in the 
presence  of  vehicle  for InsP1, InsPp, and InsPB were 1083 f 105,  196 
f 3, and 576 f 23, respectively,  with  most of this radioactivity  (see 
figure  legends  below)  representing counts/min present in the T = 0 
blank  sample. The values  given are the mean f S.E. of quadruplicate 
determinations and are representative of three experiments. *, the 
increase in inositol  phosphate  formation  due to agonist stimulation 
was significantly  greater than vehicle control ( p  < 0.05). 
TABLE I
Differentiul effects of short-term or long-term PMA pretreatment on 
agonist-stimulated inositol phosphate accumulation in WE cells 
WB cells were labeled overnight  with 4 pCi/ml  [3H]inositol and 
pretreated for the final 15 min  or 18 h of this labeling  period  with 
0.01% MeZSO or 600 nM PMA. Cells were then challenged with 
vehicle (0.1% BSA), or the indicated  agonists  for 15 min. Samples 
were assayed for [3H]inositol phosphates by anion exchange chro- 
matography. Initial resting levels of radioactivity were subtracted 
from the values  presented. The data are the mean f S.E. of quadru- 
plicate determinations and are representative of four experiments. 
(aH]Inositol  phosphate accumulation 
Treatment +PMA (600 nM) 
Control 
15-min pretreat 18-h metreat 
cpm f S.E. cpm f S.E. cpm f S.E. 
Vehicle 23 f 45  83 f 47  128 f 85 
EGF (300 ng/ml) 354 f 64 35 f 58" 629 f 53b 
Epinephrine (10 p ~ )  587 f 47 58 f 111" 733 f 55 
Angiotensin 11 (1 NM) 1407 f 163  253 f 116"  3547 f 238b 
The increase in inositol  phosphate  formation to agonist  in  PMA- 
treated cells  is  significantly  less than that in  control  cells ( p < 0.05). 
The increase  in  inositol phosphate formation to agonist  in  PMA- 
treated cells is significantly greater than that in  control  cells ( p  < 
0.05). 
stimulated InsP formation (data not shown). The changes 
observed  after  long-term  treatment  with PMA also were de- 
pendent  on  the  concentration of PMA. That is, lower concen- 
trations of PMA (0.1-10 n M )  resulted  in  attenuation of hor- 
mone responsiveness, whereas a marked concentration-de- 
pendent  potentiation of the agonist-induced InsP response 
occurred with higher  concentrations of phorbol  ester (0.1-10 
p ~ ;  Fig. 3). Under these  conditions,  pretreatment  with 10 p~ 
PMA resulted  in a 6-fold  increase  in  angiotensin 11-stimulated 
InsP  response  measured  over a 15-min period. No change in 
the  light microscopic appearance of confluent,  contact-inhib- 
ited cells was observed after 18 h with 10 p~ PMA. Long- 
term  pretreatment of cells with  10 p~ PMA  also  resulted  in 
a marked increase in the  EGF and [Arg]vasopressin InsP 
responses  (data  not  shown)  but  did  not  alter  the  epinephrine- 
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FIG. 2. PMA-induced potentiation of epidermal growth fac- 
tor- and angiotensin 11 (ANG In-stimulated inositol phos- 
phate formation in WB cells. WB  cells  were  labeled  for 18 h with 
4 pCi/ml [3H]inositol in the presence of 0.01% Me&O  (-PMA; 0) or 
600 nM PMA (+PMA; 0) and then treated with epidermal growth 
factor (left panel), or angiotensin I1 (right panel) at the indicated 
concentrations for 15 min in the presence of 10 mM LiCl. Samples 
were assayed for total [3H]inositol phosphates by anion exchange 
chromatography. The values of radioactivity accumulated in the 
presence of vehicle  were 579 f 12 and 546 f 14 cprn for  control and 
PMA-pretreated cells, respectively, and were subtracted from the 
values  presented. The data are presented as the mean of triplicate 
determinations and are representative of two experiments. 
0 3 1 0 8 6  
-log [PMA] 
FIG. 3. Differential modification of angiotensin II-stimu- 
lated inositol phosphate formation in WB cells after short- 
term or long-term pretreatment with PMA. WB cells were 
labeled  overnight  with 5 pCi/ml [3H]inositol and pretreated for the 
final 18 h (0) or 15 min (0) of this labeling  period  with 0.01% Me2S0 
or the indicated concentrations of  PMA.  Cells  were then challenged 
with vehicle  or 1 p M  angiotensin I1 for 15 min.  Samples  were  assayed 
for  [3H]inositol  phosphates by anion  exchange  chromatography.  An- 
giotensin 11-stimulated increases in inositol phosphates in control 
cells  were 1124 f 8 and 1108 f 12 cpm  for 18-h and 15-min  experi- 
ments,  respectively, and were  defined as 100% response.  Each  value 
is the mean f S.E.  of triplicate determinations. 
mediated  accumulation of InsP  (see below). 
As shown  in Fig. 4, the  time  course  for  modulation of the 
InsP  response  by  PMA  (10 p ~ )  was clearly biphasic. Brief 
pretreatment inhibited the InsP response to a maximally 
effective concentration (1 pM) of angiotensin 11. An 85% 
blockade of the  response was observed within  the first 5 min, 
and loss of response  was  maintained  for  up  to  60  min (Fig. 4). 
Within 2 h, the inhibitory effects of PMA on the InsP 
response were lost,  and  with  extended  preincubation  times a
time-dependent  potentiation of the InsP response occurred. 
After 10 h of pretreatment, the levels of InsP formed in 
response  to a 10-min  challenge  with  agonist were potentiated 
by  approximately 4-fold (Fig. 4). This  potentiation was main- 
tained  for at least 24 h in  the  continued  presence of PMA. 
Since  long-term  pretreatment of cells with  phorbol  ester 
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has been reported to down-regulate protein kinase C (3, 15- 
18), the activity of protein kinase C was measured directly in 
cytosolic and particulate fractions prepared from WB cells 
pretreated for 18 h with PMA. As shown in  Table 11, pretreat- 
ment of WB cells with 600 nM and 10 p M  PMA resulted in  a 
90-100% loss of measurable protein kinase C activity as 
assessed by phosphatidylserine/diacylglycerol-induced 32P 
labeling of substrate (HPLC-purified N-bromosuccinimide 
cleavage fragment of lysine-rich histone). 
A  time course for agonist-induced InsP formation of WB 
cells revealed that maximally effective concentrations of an- 
giotensin I1 and epinephrine each stimulated a rapid accu- 
mulation of InsP. However, accumulation of InsP  in response 
Pretreatment with PMA (hr) 
FIG. 4. Time course for PMA-induced modification of the 
angiotensin II-stimulated  accumulation of inositol phos- 
phates. WB cells were labeled overnight with 5 pCi/ml of [3H]inositol 
in the presence of 10 PM PMA or 0.01% Me2S0 for the indicated 
times. Following preincubation, cells were challenged with 1 ptM 
angiotensin I1 or vehicle in the presence of 10 mM LiCl for 10 min 
and assayed for the accumulation of [3H]inositol phosphates. At each 
time  point, angiotensin I1 stimulation after PMA pretreatment was 
compared to angiotensin I1 stimulation after  Me2S0  treatment.  The 
fold stimulation due to angiotensin I1 over vehicle was arbitrarily 
defined as 100% maximal stimulation for each time. Each value is 
the mean of triplicate  determinations and  the  data re representative 
of two experiments. 
to both agonists was essentially maximal within 60 s (Fig. 5). 
Chronic pretreatment (18 h) with 10 p~ PMA produced 
markedly different effects on response to  the two agonists. 
Whereas PMA pretreatment had no effect on the time course 
of accumulation of InsP in the presence of epinephrine (Fig. 
5, right), phorbol ester  pretreatment markedly sensitized the 
inositol phosphate pathway to angiotensin I1 stimulation (Fig. 
5, left). Thus  the “fold stimulation” produced by angiotensin 
I1 was 4-, 6-, and 9-fold after  a lo-, 15-, and 20-min stimula- 
tion, respectively. Under these conditions, basal accumulation 
of InsP was not augmented by long-term pretreatment with 
PMA. A more detailed time course for the initial 90 s of the 
angiotensin 11-stimulated InsP response in PMA-pretreated 
uerszu control cells is presented in Fig. 6. Angiotensin II- 
stimulated InsP accumulation was maximal within 30 s after 
hormone addition to control cells. In contrast, the accumula- 
tion of InsP  in PMA-pretreated cells was greater than  that 
observed in control cells, and after 30 s InsP continued to 
accumulate, although at a slower rate than initially. 
One interpretation of data presented thus far is that, fol- 
lowing long-term pretreatment of WB cells with PMA, angio- 
tensin I1 (and  other) receptor-mediated stimulation of phos- 
pholipase C does not result in desensitization of the receptor/ 
phospholipase C response system. Experiments were carried 
out to demonstrate more directly that  this was the case  (Fig. 
7). Control and PMA-pretreated (10 p ~ ,  18 h) cells were 
incubated with 1 p M  angiotensin I1 for 30 min in the absence 
of LiC1. The cells were then rapidly washed free of agonist 
and fresh medium  was added containing angiotensin I1 (1 p ~ )  
and LiCl (10 mM). Since LiCl inhibits  InsP, metabolism (2), 
it was reasoned that any phosphoinositide hydrolysis still 
occurring in the angiotensin 11-pretreated cells would  be de- 
tected as an increase in total InsP after rechallenge with 
angiotensin I1 plus LiC1. In  contrast to  the situation in control 
cells where readdition of angiotensin I1 and LiCl elicited only 
a very small increase in InsP, readdition of this hormone plus 
LiCl to PMA-pretreated cells resulted in a large accumulation 
of InsP which  was maintained at a linear rate for at least 30 
min (Fig. 7, 30-min time point  not shown). The data suggest 
that  the difference in hormone responsiveness between con- 
TABLE I1 
Protein kinase C activity after long-term PMA treatment 
WB cells were maintained for 18 h in the absence or presence of PMA. Homogenates were then prepared and 
protein kinase C activity, i.e. phosphatidylserine + diacylglycerol (PS/D)-induced [32P]phosphorylation of sub- 
strate, was determined as described under “Experimental Procedures.” The  data are the mean results of three and 
two separate  experiments for the low PS/D  and high PS/D, respectively, and each experiment consisted of triplicate 
determinations.  Blank levels of 32P radioactivity (PS/D-induced phosphorylation in the absence of substrate) were 
subtracted from the values Dresented. 
Kinase  activity 
Protein  kinase C activity 
Cytosolic Soluble particulate 
+PMA  +PMA +PMA +PMA Control 600 nM  10 pM 600 nM 10 pM Control 
a. Low phosphatidylserine (63 phi) and 
diacylglycerol(39 p ~ )  
Basal 
Phosphatidylserine + diacylglycerol 
Protein kinase activity 
% Control  protein kinase C activity 
b. High phosphatidylserine (600 PM) and 
diacylglycerol (80 p ~ )  
Basal 
Phosphatidylserine + diacylglycerol 
Protein kinase C activity 
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FIG. 5. Differential effects of  long-term PMA pretreatment 
on the  time  course of angiotensin I1 (ANG 11)- and  epineph- 
rine-stimulated  inositol phosphate  accumulation  in WB cells. 
WE3 cells were labeled for 18 h with 5 pCi/ml [3H]inositol in the 
presence of 0.01% MezSO (0) or 10 p~ PMA (0) and then challenged 
with  vehicle (+), 1 pM angiotensin I1 (ANG ZI, left panel), or 10 p~ 
epinephrine (EPI, right p a n e l )  in the presence of 10 mM LiCl for the 
indicated  times.  Samples  were  assayed  for the accumulation of I3H] 
inositol  phosphates by anion  exchange  chromatography. Initial (T = 
0) resting levels  of radioactivity in PMA- and MezSO-pretreated cells 
were 2681 f 129 and 2260 k 86, respectively, and were subtracted 
from the values  presented. The data are the mean k S.E. of triplicate 
determinations and are representative of three experiments. 
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FIG. 6. Potentiation of angiotensin 11-stimulated inositol 
phosphate  accumulation after long-term PMA pretreatment. 
WB cells were labeled for 18 h with 5 pCi/ml [3H]inosi~l in the 
presence of 0.01% MezSO (0) or 10 p~ PMA (0) and then challenged 
with 1 p~ angiotensin I1 (0,O) or  vehicle (+) for the indicated times. 
Samples  were  assayed for the accumulation of [3H]inositol  phosphates 
by anion exchange  chromatography. Initial (T = 0) resting levels of 
radioactivity in PMA- and MezSO-pretreated cells were 3196 f 76 
and 3586 f 107,  respectively, and were subtracted from the values 
presented. The data are the mean f S.E. of triplicate  determinations. 
troland  long-term  PMA-pretreated WB cells can  be  explained 
at least  in part by a reduction  in  the  extent of agonist-induced 
desensitization  in  the  PMA-pretreated cells. 
Since  long-term  PMA  pretreatment influenced the relative 
rate of formation of InsP to agonists, it is possible that 
substrate, i.e. phosphoinositide, levels and/or  the specificity 
of phospholipase C for the different lipids was altered. To 
investigate these possibilities, we measured angiotensin II- 
induced changes over time  in  the levels of the  phosphoinosi- 
tides  PtdIns,  PtdIns-4-P,  and  PtdIns(4,5)P2  and  the individ- 
0- 
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FIG. 7. Blockade of angiotensin 11-induced desensitization 
of the  inositol  phosphate  response  in WB cells by long-term 
PMA pretreatment. WB cells were pretreated for 18 h with ['HI 
inositol  in the presence of 0.01% MeZSO (0, 0) or 10 pM PMA (0, 
B) and then challenged  with 1 p~ angiotensin I1 (0, B) or  vehicle (0, 
0) for 30 min in the absence of LiC1. The medium was rapidly 
aspirated, and the cells were rechallenged at T = 0 with  fresh medium 
containing 1 p~ angiotensin I1 (0, B) or vehicle (0,O) in the presence 
of 10 mM LiC1. Samples were collected at the indicated times and 
were assayed for the accumulation of total [3H]inosi~l phosphates 
by anion exchange  chromatography. The data are the mean & S.E. of 
triplicate  determinations and are representative of three experiments. 
ual  inositol  phosphates (Fig. 8). Chronic  pretreatment of cells 
with  PMA did not increase  [3H]inositol  labeling of phospho- 
lipids  since initial levels of radioactivity associated  with each 
of the  phosphoinositides were essentially  the  same  in  PMA 
pretreated and control cells (see legend, Fig. 8). In control 
cells, angiotensin I1 stimulated a rapid, albeit  transient, 20 
and 25% decrease in radioactivity  associated with  PtdIns(4,5) 
P, and PtdIns-4-P levels, respectively, over the  initial 60 s 
(Fig. 8, left); lipid levels returned  to  initial values within 5 
min.  Significant  changes  in  PtdIns levels were not observed. 
In  contrast, a more rapid  and  pronounced 70 and 50% reduc- 
tion  in radioactivity associated with PtdIns(4,5)Pz  and 
PtdIns-4-P levels, respectively, occurred  within  the  first 30 s 
of challenge of PMA-pretreated cells with  angiotensin I1 (Fig. 
8, left). Lipid levels gradually returned  to  initial evels over a 
10-min period. As with  control cells, significant changes in 
PtdIns levels were not observed. The  relative  ratios of the 
levels of radioactivity  associated with  PtdIns,  PtdIns-4-P,  and 
PtdIns(4,5)P2 were 100:5.4:4.3, respectively, in control cells 
and 1005.2:4.0, respectively, in  PMA-pretreated cells. 
Consistent  with  results  obtained by measuring total  InsP 
levels, angiotensin 11-stimulated accumulation of InsP, InsP,, 
and  InsP3 was potentiated  in  PMA-pretreated cells (Fig. 8, 
right). In  control cells, agonist  stimulated a rapid  although 
transient rise in Imp3  and InsP, levels; maximal levels for 
both  inositol  phosphates were obtained  within 60 s. Elevated 
levels returned  to base line  within 5 min. InsP, levels were 
unchanged over the 1st min,  and  then a linear  accumulation 
was  observed  for up to 20 min. PMA  pretreatment  resulted 
in a pronounced increase in  the  rate of accumulation of all 
three  InsP (Fig. 8, right). InsP, levels were enhanced slightly 
over the 1st min  and  accumulated linearly at an accelerated 
rate  in  PMA-treated cells as  compared  to  control cells  for up 
to  20 min (Fig. 8, right); angiotensin I1 stimulated a rapid rise 
in  the levels of both  InsP,  and  InsP,  in  the 1st min which 
continued after 1 min at a slower rate for up to 20 min. 
Measurement of the two  isomers of InsP,,  Ins(1,4,5)P3 and 
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FIG. 8. Potentiation  of  angiotensin 11-stimulated turnover 
of  phosphoinositides  and  formation  of  inositol  phosphates  in 
W B  cells by long-term  pretreatment  with PMA. WB cells were 
treated for 18 h with 5 pCi/ml [3H]inositol in the presence of 0.01% 
MezSO (0, .) or  10 p~ PMA (0, .) and  then challenged with 1 p~ 
angiotensin I1 (0,O) or vehicle (13, B) for the indicated times. Samples 
were assayed for changes in levels of the 3H-labeled phosphoinosi- 
tides, PtdIns(4,5)Pz (PIP,, left top), PtdIns-4-P (PZP, left middle), 
and  PtdIns (PI, left bottom), and for accumulation of the 3H-labeled 
inositol phosphates, InsP3 (right top), InsPz (right middle), and  InsP, 
(right bottom) as described under "Experimental Procedures." Angio- 
tensin 11-stimulated changes in the levels of each individual phos- 
phoinositide were expressed as a percentage of initial (T = 0) resting 
levels, defined as 100%. Initial levels of 3H radioactivity in 
PtdIns(4,5)P2, PtdIns-4-P,  and  PtdIns were  1,892 f 30,  2,421 f 128, 
and 44,379 f 2,255 cpm, respectively, in Me&O-treated cells, and 
1,532 * 70,  2,031 f 15 and 38,683 f 71 cpm, respectively, in PMA- 
treated cells. Background (T = 0) levels for InsP3, InsPz,  and  InsP 
were 171 f 8,220 f 17, and 2,150 f 121 cpm, respectively, in Me2SO- 
treated cells, and 179 f 5,233 f 19, and 2,781 f 40 cpm, respectively, 
in  PMA-treated cells and were subtracted from the values presented. 
The  data  are  the mean f S.E. for three determinations. 
Ins( 1,3,4)P3, during  stimulation with angiotensin I1 revealed 
that long-term pretreatment of the cells with PMA results  in 
an increase in the initial  rate of accumulation of Ins( 1,4,5)P3 
as compared to control cells (Fig. 9). After the 1st min of 
incubation with angiotensin 11, the levels of Ins(1,4,5)P3 fell 
to a new steady state, reflecting a sustained,  enhanced  rate of 
formation. Further evidence for this was observed by the 
enhanced  rate of accumulation of Ins(1,3,4)P3, a metabolic 
product of Ins(1,4,5)P3  in  PMA-treated cells. Unlike those of 
Ins(1,4,5)P3, the levels of Ins(1,3,4)P3 did not  establish steady 
state  but  rather continued to rise over a 15-min period (Fig. 
9), perhaps due in  part  to  the presence of 10 m M  LiCl, an 
inhibitor of the 1-phosphomonoesterase responsible for me- 
tabolism of Ins(1,3,4)P3 (30). 
It has been reported that activation of protein kinase C by 
phorbol esters  results  in the phosphorylation and activation 
of a 5'-phosphomonoesterase resulting in an increased rate of 
degradation of inositol phosphates (31, 32). To test if the 
observed increase in  the hormone-stimulated levels of InsP 
after chronic pretreatment of WB cells with phorbol ester was 
a partial consequence of an altered rate of degradation of 
InsP, we measured the  rate of disappearance of exogenously 
added [3H]Ins(1,4,5)P3 and  the  rate of appearance of InsPl 
and InsP, in homogenates prepared from control  and PMA- 
minutes Elution Time (minutes) 
FIG. 9. PMA-induced  potentiation  of  angiotensin  II-stimu- 
lated accumulation of Ins(l,4,6)P3 and Ins(1,3,4)Ps in WB 
cells. h f t  side, WB cells were labeled for 18 h with 10 &i/ml [3H] 
inositol in the presence of 0.01% Me2S0 (0, 0) or  10 p~ PMA (0, 
.) and  then challenged with vehicle (0, .) or angiotensin I1 ( 0 , O )  
in the presence of 10 mM LiCl for the indicated times. Samples were 
assayed for the accumulation of InsP3 isomers by HPLC  as described 
under "Experimental Procedures." The  data re single determinations 
and are representative of two experiments. Right side, HPLC elution 
profile of [3H]InsP3 isomers isolated from WB cells pretreated with 
0.01% MezSO or 10 p~ PMA for 18 h. Elution profiles depict 3H 
radioactivity that coeluted with standards of Ins(1,3,4)P3 and 
Ins(1,4,5)P3, indicated by the arrows, in unstimulated WB cells ex- 
posed to 10 mM LiCl (T = 0, top) or in cells stimulated with 1 WM 
angiotensin I1 for 5 s, 1 min, or 5 min in the presence of 10 mM LiCl. 
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FIG. 10. Lack  of effect of  long-term PMA pretreatment on 
the  rate of degradation  of  Inspa  in WB homogenates. WB cells 
were pretreated for 18 h with 0.01% MezSO (open symbols) or 10 PM 
PMA (closed symbols), rapidly lysed, and prepared as homogenates as 
described under "Experimental Procedures." The homogenates were 
incubated in the ,presence of intracellular buffer and exogenously 
added [3H]Ins(1,4;5)P3 at 37  'C for the indicated times, and samples 
were assayed for the presence of 3H radioactivity in InsP3 (0, O), 
InsP2 (A, A), and InsP, (0, W) by anion exchange chromatography. 
The  data are expressed as  the mean f S.E. of triplicate determina- 
tions and are representative of two experiments. 
pretreated WB cells (Fig. 10). PMA pretreatment  and down- 
regulation of protein kinase C did not  alter  the rate of deg- 
radation Ins(1,4,5)P3 or the rate of formation of InsP,  and 
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FIG. 11. Differential effects of PMA pretreatment on ino- 
sitol phosphate formation by NaF and angiotensin I1 in intact 
WB cells. WB cells were labeled overnight with 5 pCi/ml [3H] 
inositol. h / t  side, WB cells were pretreated for the final 18 h of the 
labeling  period  with 0.01% Me2S0 (open circles; -, white bar) or 10 
phi  PMA (closed circle; +, hatched bar), challenged with vehicle, NaF 
(circles) at the indicated concentrations, or 1 p~ angiotensin I1 (ANG 
ZZ, bars) in the presence of 10 mM LiCl  for 15 min, and then assayed 
for total [3H]inositol  phosphates by anion exchange  chromatography. 
Right side, WB cells were pretreated for the final 15 min of the 
labeling  period  with 0.01% Me2S0 (-, white bars) or 10 p~ PMA (+, 
hatched bars), challenged  with  vehicle, 30 mM NaF’, or 1 pM angioten- 
sin I1 for 15 min, and then assayed for total [3H]inositol  phosphates 
by anion exchange  chromatography.  Levels of radioactivity  accumu- 
lated in the presence of vehicle were subtracted from each value 
presented. The data are the mean & S.E. of triplicate determinations 
and are representative of two experiments. 
+PMA r 
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FIG. 12. Stimulation of inositol phosphate formation by 
guanine nucleotide and angiotensin I1 in washed membranes 
prepared from control and PMA-pretreated cells. WB cells 
were preincubated with 10 pCi/ml [3H]inositol in the presence of 
0.01% Me2S0 (left panel) or 10 pM PMA (right panel) for 18 h and 
prepared as washed membranes as described under “Experimental 
Procedures.”  Membranes  were  incubated at 37 “C for 15 min in assay 
buffer containing the indicated concentrations of GTPyS in the 
absence (0) or presence (0) of angiotensin 11, and samples were 
assayed for total [3H]inositol phosphates by anion exchange chro- 
matography. The data are the mean of triplicate determinations and 
represent pooled results from two separate  experiments. 
InsP,  in  WB homogenates. 
Hormone-stimulated  activation of phospholipase  C in- 
volves a G-protein (26, 33-41), and  thus  NaF, a well known 
activator of G-proteins,  stimulates  InsP  formation  in mem- 
brane  preparations  (36,38,39)  and  in  intact cells (40,41).  To 
determine if chronic  PMA  pretreatment modified G-protein- 
stimulated InsP formation, we measured levels of InsP in 
intact control and PMA-treated WB cells challenged with 
NaF. As  shown in Fig. 11 (left), NaF  stimulated  the accumu- 
lation of InsP  in a concentration-dependent  manner.  Chronic 
pretreatment of the cells with PMA resulted in a marked 
potentiation of the  angiotensin 11-stimulated InsP response 
but was without effect on  the  NaF-stimulated  InsP response 
(Fig. 11, left). Similarly, acute  activation of protein  kinase C 
by PMA inhibited the angiotensin 11-stimulated InsP re- 
sponse by 85% but  did  not  alter  the levels of InsP formed in 
response to  NaF  stimulation (Fig. 11, right). 
To  test  further  the role of protein  kinase C in regulation of 
agonist  and  G-protein-mediated  InsP  formation, we measured 
the formation of InsP in response to the nonhydrolyzable 
analogue of GTP,  GTPyS,  in  the  presence  and absence of 
angiotensin I1 in washed membranes  prepared from WB cells 
(Fig. 12).  In  control cells GTPyS  stimulated  InsP  formation 
in a concentration-dependent  fashion with a KO., of approxi- 
mately 3 PM (Fig. 12, left). A maximally effective concentra- 
tion of angiotensin 11, although ineffective  alone, potentiated 
the  InsP response to  guanine nucleotide at all  concentrations 
(Fig. 12, left). Chronic pretreatment with phorbol ester did 
not  alter  the l vels of InsP accumulated  in  response to guanine 
nucleotide or agonist  plus  guanine nucleotide (Fig. 12, right). 
Short-term (20 min)  pretreatment of WB cells with 10 PM 
PMA also did  not  alter  the levels of InsP formed in response 
to GTPyS in washed membrane  preparations  (data  not 
shown). 
DISCUSSION 
Hormone  receptor-stimulated  PtdIns(4,5)P2 hydrolysis, 
InsP  formation,  and  the  subsequent rise  in cytosolic Ca2+  can 
be abolished  by short-term  activation of protein  kinase C (2, 
4-10). These  observations suggest that  protein  kinase C  may 
play a regulatory role in receptor-stimulated PtdIns(4,5)P2 
hydrolysis. One  prediction  inherent  in  this idea would be that 
blockade or loss of protein  kinase C activity would result  in 
an increased  responsiveness of the  phosphoinositide signaling 
pathway to  hormone  stimulation. To address  this  question, 
we have  characterized  hormone-  and growth factor-stimulated 
InsP  formation  under  conditions where protein  kinase C has 
been down-regulated by long-term exposure to  the phorbol 
ester, PMA. 
The  present findings demonstrate  that long-term pretreat- 
ment of WB cells  with PMA  results  in a marked  sensitization 
of the phosphoinositide signaling  pathway  to hormone and 
growth factor stimulation. This observed effect of phorbol 
ester  pretreatment could  occur by at  least two  possible  means: 
(a) some component(s) in the phosphoinositide signaling 
pathway could be modified resulting in a system that is 
inherently more responsive to hormone stimulation, or (b)  
agonist-induced desensitization of the phosphoinositide sig- 
naling  pathway may no longer  occur  due to down-regulation 
of protein  kinase C and  the loss of protein  kinase  C-mediated 
negative  feedback inhibition.  The  present  data  are  consistent 
with  the  latter idea. Kinetic  analysis  indicated  that  hormone- 
induced desensitization of the  phosphoinositide signaling  sys- 
tem occurs  rapidly in  WB cells. Desensitization may  occur  by 
more than  one  mechanism  in  these cells, but several  lines of 
evidence suggest that responsiveness is regulated at least  in 
part  through  activation of protein  kinase C with  consequent 
feedback inhibition of responsiveness. Consistent with this 
conclusion from kinetic analyses, short-term activation of 
protein kinase C with phorbol ester results in a marked 
inhibition of hormone-stimulated  InsP  formation  in  WB cells 
and  many  other  tissues (2, 4-10). Additionally, sensitization 
of the  phosphoinositide  pathway  to  hormone  stimulation  in 
WB cells after  long-term  pretreatment with  phorbol ester  is 
correlated  with a loss of measurable  protein  kinase C activity 
and a concomitant loss of phorbol  ester responsiveness. 
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The conclusion that  the increased hormone responsiveness 
occurring after down-regulation of protein kinase C is at least 
in part explained by a lack of protein kinase C-mediated 
agonist-induced desensitization upon hormone challenge is 
supported by several other observations. First, it has been 
reported in several tissues that activation of protein kinase C 
by phorbol ester  results  in phosphorylation and activation of 
a 5’-phosphomonoesterase responsible for the conversion of 
Ins(1,4,5)P3 to  Ins(l,4)Pp (31, 32). This does not  appear to be 
a major contributing factor in WB cells since the altered 
kinetics of InsP accumulation could not be explained by a 
simple change in  the  rate of metabolism of Ins(1,4,5)P3  and 
direct  analysis of metabolism of inositol phosphates in WB 
cell lysates failed to reveal any major PMA-induced alteration. 
Second, short-term phorbol ester  pretreatment of certain cells 
stimulates an increased rate of labeling of PtdIns(4,5)Pz (42, 
43) and  an increase in  the levels of InsP formed to subsequent 
hormone stimulation (43). However, down-regulation of pro- 
tein kinase C in WB cells did not  alter  either  the  amount of 
radioactivity associated with phosphoinositides or the relative 
distribution of label among the  three phosphoinositides. 
Receptor-mediated activation of phospholipase C involves 
a yet-to-be identified G-protein (33-39). At least one well 
characterized G-protein  has been shown to be phosphorylated 
by protein kinase C (44) and  it  is possible that protein kinase 
C could alter hormone-stimulated InsP formation by inhib- 
iting the action of the involved G-protein. Consistent with 
this idea are the recent observations that hormone- and 
guanine nucleotide-stimulated InsP formation in washed 
membranes prepared from 1321N1 astrocytoma cells (45) and 
polymorphonuclear leukocytes (46)  after  short-term  pretreat- 
ment with phorbol ester was partially  attenuated  as compared 
to control membranes. This effect of phorbol ester  in  astro- 
cytoma cells was mimicked to a limited extent by the addition 
of purified protein kinase C (45). The present  results suggest 
that  in  WB cells, protein kinase C does not regulate agonist- 
stimulated  PtdIns(4,5)P2 hydrolysis by altering the capacity 
of the involved G-protein to active phospholipase C. That is, 
guanine nucleotide-stimulated InsP formation in washed 
membranes prepared from WB cells after  short-term  or long- 
term  pretreatment with PMA was not significantly different 
from control. Furthermore,  NaF-stimulated formation of InsP 
in  intact cells remained unchanged under conditions where 
the hormone-stimulated response was markedly altered  either 
by short-term  or long-term PMA pretreatment.  In  contrast 
to the change in response observed with intact cells, InsP 
formation in  the presence of guanine nucleotide plus angio- 
tensin I1 was the same in washed membranes prepared from 
control cells as  in membranes from protein kinase C down- 
regulated cells. Since greater than 80% of the measurable 
protein kinase C activity in  unstimulated  WB cells is cytosolic 
(Table 11), a washed membrane preparation from untreated 
cells would contain  a very limited amount of protein kinase 
C. Clearly, other cytosolic factors that are critical for the 
regulation of hormone-stimulated PtdIns(4,5)P2 hydrolysis 
also could be lost in a washed membrane preparation. 
Acute pretreatment of Swiss 3T3 cells with phorbol ester 
results  in  inhibition of bombesin-stimulated InsP formation 
but  not platelet-derived growth factor-stimulated effects (47). 
Similarly, acute activation of protein kinase C by phorbol 
ester  in primary cultures of rat hepatocytes selectively inhibits 
the cui-adrenergic receptor-mediated InsP formation  but 
leaves the vasopressin- and the angiotensin 11-stimulated 
responses relatively unimpaired (48, 49). Although this find- 
ing is in contrast to the present results where short-term 
exposure of WB cells to phorbol ester  inhibited  al-adrener- 
pic, angiotensin 11-, and [Ar$]vasopressin-stimulated InsP 
formation, these  reports  illustrate that phorbol esters  inhibit 
agonist-stimulated InsP formation in a receptor- and tissue- 
selective manner. Such selectivity of action is consistent with 
the idea that protein kinase C  acts at  the level of the receptor 
rather than  at a common point of convergence in the pathway 
such as  a  G-protein or the effector enzyme, phospholipase C. 
The present  results also provide  evidence in support of this 
idea. First, agonist-stimulated PtdIns(4,5)P2 hydrolysis was 
markedly altered by  PMA treatment while that mediated by 
G-protein remained unimpaired. Second, although short-term 
pretreatment with PMA resulted in inhibition of angiotensin 
11- and epinephrine-stimulated InsP formation, long-term 
pretreatment resulted in a markedly different change in re- 
sponsiveness to these two agonists. That is, the  InsP response 
to epinephrine was similar to  that observed in control cells, 
but InsP accumulation in response to angiotensin I1 (and 
EGF  and [Ar$]vasopressin) were enhanced significantly over 
control responses. The reason for this selective sensitization 
of the phosphoinositide pathway for one receptor but not 
another is not clear. Perhaps activation of al-adrenergic 
receptors results in homologous receptor desensitization by 
more than one mechanism, i.e. one mechanism that is protein 
kinase C-dependent and one that does not require protein 
kinase C.  If such were the case, then down-regulation of 
protein kinase C would not necessarily be expected to increase 
the  InsP response to al-receptor stimulation. 
The current  data  cannot completely rule out the possibility 
that phorbol esters sensitize the phosphoinositide signaling 
pathway by an action that occurs in parallel with down- 
regulation of protein kinase C. Within the sensitivity limits 
of the assay, long-term exposure of WB cells with both the 
lower, i.e. 600 nM, and the higher, i.e. 10 p ~ ,  concentrations 
of PMA caused similar 90-100% losses of protein kinase C 
activity. However, pretreatment with the higher concentra- 
tion consistently elicited a more pronounced potentiation of 
hormone responsiveness. The reason for this phenomenon is 
not clear. It is conceivable that  at high concentrations, PMA 
acts  to impair other protein kinases or processes in addition 
to protein kinase C. Alternatively, it is possible that unde- 
tectably small amounts of active protein kinase C remain 
after chronic pretreatment with the lower but  not the higher 
concentration of PMA. Thus we cannot rule out the possible 
contribution of a small residual amount of protein kinase C 
activity that imposes a negative regulation, albeit very modest, 
on the phosphoinositide signaling pathway. Cells pretreated 
with the higher concentration of phorbol ester presumably 
would  be under no such negative regulation and  thus capable 
of eliciting a relatively greater response to agonist stimulation. 
Further  studies will  be necessary to determine whether phor- 
bo1 esters  alter hormone responsiveness by  modifying protein 
kinase C activity alone. 
Agonist-induced desensitization is a property shared by a 
variety of cell surface receptors, and several molecular mech- 
anisms apparently are involved in this process. Many hor- 
mone receptors undergo agonist-induced internalization as  a 
mechanism for reducing the cells capacity to respond to 
subsequent hormonal stimulation. Recently, it has been 
shown that receptor phosphorylation by specific receptor 
kinases (50,51) or CAMP-dependent protein kinase (52) may 
be important  in regulation of receptor responsiveness to stim- 
ulation by agonist. Little is known about the mechanisms 
involved in agonist-induced desensitization of receptors 
linked to  PtdIns(4,5)P2 hydrolysis, although a regulatory role 
for protein kinase C in this process has been suggested by 
several studies. For example, protein kinase C-stimulated 
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phosphorylation of the al-adrenergic receptor has been shown 
to be correlated with a decrease in affinity for agonist binding 
and  a marked attenuation  in  a,-receptor agonist-stimulated 
turnover of phosphoinositides (53). Similarly, EGF  stimulates 
PtdIns(4,5)P2 hydrolysis (54-56) and Ca2+ mobilization (56- 
58) in A431 epidermoid carcinoma cells and  short-term  acti- 
vation of protein kinase C by phorbol ester in these cells 
results  in phosphorylation of the  EGF receptor (59, 60) and 
loss of EGF-stimulated InsP formation (54) and Ca2+ mobi- 
lization (57,58).  In  addition, phorbol esters have been shown 
to increase markedly the  rate of internalization of the  EGF 
receptor on KB  human epidermoid carcinoma cells (61) and 
WB The present  results  are  consistent with the idea 
that protein kinase C activation provides a negative feedback 
regulation of hormone-induced PtdIns(4,5)P2 hydrolysis and 
Ins( 1,4,5)P3 production; angiotensin I1 receptor-mediated 
PtdIns(4,5)P2 hydrolysis very rapidly undergoes agonist-in- 
duced desensitization, and  this process can be prevented by 
long-term pretreatment with phorbol esters  and  a consequen- 
tial down-regulation of protein kinase C. In support of these 
observations in WB cells, Brown and co-workers (20) very 
recently reported, and we have c~nfirmed,~  that  bombesin- 
stimulated accumulation of inositol phosphates in Swiss 3T3 
cells also is potentiated after long-term pretreatment with 
phorbol ester. Since DAG is also a product of PtdIns(4,5)P2 
hydrolysis and  an endogenous activator of protein kinase C, 
then one result of hormone-induced increases in DAG levels 
and activation of protein kinase C may  be the negative feed- 
back regulation of the phosphoinositide signaling pathway to 
further agonist stimulation.  WB cells should provide a useful 
model system for the further study of the role of protein 
kinase C in these processes. 
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